Advertisement
Research ArticleDrug Discovery and Translational Medicine

TransCon CNP, a Sustained-Release C-Type Natriuretic Peptide Prodrug, a Potentially Safe and Efficacious New Therapeutic Modality for the Treatment of Comorbidities Associated with Fibroblast Growth Factor Receptor 3–Related Skeletal Dysplasias

Vibeke Miller Breinholt, Caroline E. Rasmussen, Per Holse Mygind, Mads Kjelgaard-Hansen, Frank Faltinger, Ana Bernhard, Joachim Zettler and Ulrich Hersel
Journal of Pharmacology and Experimental Therapeutics September 2019, 370 (3) 459-471; DOI: https://doi.org/10.1124/jpet.119.258251
Submit a Response to This Article
Compose eLetter

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleDrug Discovery and Translational Medicine

Sustained-Release CNP Prodrug in Achondroplasia

Vibeke Miller Breinholt, Caroline E. Rasmussen, Per Holse Mygind, Mads Kjelgaard-Hansen, Frank Faltinger, Ana Bernhard, Joachim Zettler and Ulrich Hersel
Journal of Pharmacology and Experimental Therapeutics September 1, 2019, 370 (3) 459-471; DOI: https://doi.org/10.1124/jpet.119.258251
Reddit logo Twitter logo Facebook logo Mendeley logo

Jump to section

Advertisement